Compare AG & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | HALO |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.9B |
| IPO Year | 2004 | 2001 |
| Metric | AG | HALO |
|---|---|---|
| Price | $18.60 | $103.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $21.92 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 9.9M | 2.0M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.11 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $24.41 | $28.24 |
| Revenue Next Year | $10.68 | $12.56 |
| P/E Ratio | $143.01 | ★ $33.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.34 | $61.23 |
| 52 Week High | $32.00 | $104.77 |
| Indicator | AG | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 87.77 |
| Support Level | $18.43 | $62.89 |
| Resistance Level | $20.00 | N/A |
| Average True Range (ATR) | 0.75 | 3.17 |
| MACD | 0.41 | 2.18 |
| Stochastic Oscillator | 94.31 | 95.28 |
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.